Literature DB >> 971706

Decreased drug binding in serum from patients with chronic hepatic disease.

S Wallace, M J Brodie.   

Abstract

The binding of 3 drugs to serum proteins of patients with chronic hepatic disease has been studied by an ultrafilitration technique, and compared to that of normal subjects. The binding of phenylbutazone was reduced in all patients, salicylate in patients with inactive liver disease and sulphadiazine in patients whose disease was active. Analysis of binding data showed a real reduction in the capacity of albumin to bind the drugs in the majority of patients. Addition of bilirubin to normal plasma caused a reduction in sulphadiazine binding, but had no effect on the binding of salicylate or phenylbutazone. The possible causes of this reduction in binding are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971706     DOI: 10.1007/BF00606560

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Rapid determination of salicylate in biological fluids.

Authors:  P TRINDER
Journal:  Biochem J       Date:  1954-06       Impact factor: 3.857

2.  The protein binding of some drugs in plasma from patients with alcoholic liver disease.

Authors:  M Affrime; M M Reidenberg
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

Review 3.  Effect of disease states on plasma protein binding of drugs.

Authors:  M M Reidenberg
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

4.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

5.  Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease.

Authors:  W D Hooper; F Bochner; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1974-03       Impact factor: 6.875

6.  Protein binding of drugs in plasma from patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

7.  The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding.

Authors:  A Windorfer; W Kuenzer; R Urbanek
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

8.  Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants.

Authors:  A Rane; P K Lunde; B Jalling; S J Yaffe; F Sjöqvist
Journal:  J Pediatr       Date:  1971-05       Impact factor: 4.406

9.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

10.  Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding.

Authors:  L W Powell; E Axelsen
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

  10 in total
  12 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  [Pharmaco-kinetic aspects of protein-binding (author's transl)].

Authors:  H Kurz
Journal:  Klin Wochenschr       Date:  1978-12-15

4.  Investigations on salicylate protein binding in newborns and infants.

Authors:  A Windorfer; D Karitzky; U Gasteiger; K Stehr
Journal:  Eur J Pediatr       Date:  1978-03-13       Impact factor: 3.183

Review 5.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of phenylbutazone.

Authors:  J Aarbakke
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

7.  Protein binding of salicylate in cutaneous hepatic porphyria.

Authors:  W H Steele; S W Boobis; M R Moore; A Goldberg; M J Brodie; D J Summer
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

8.  Disposition of valproic acid in man.

Authors:  R Gugler; A Schell; M Eichelbaum; W Fröscher; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

10.  Decrease of in vitro serum protein binding of salicylate in rheumatoid arthritis.

Authors:  P Netter; C Monot; M C Stalars; J M Mur; R J Royer; G Faure; J Pourel; J Martin; A Gaucher
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.